Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Equity Average (2022 - 2026)

TriSalus Life Sciences has reported Equity Average over the past 5 years, most recently at -$10.5 million for Q1 2026.

  • For Q1 2026, Equity Average rose 65.06% year-over-year to -$10.5 million; the TTM value through Mar 2026 reached -$10.5 million, up 65.06%, while the annual FY2025 figure was -$29.9 million, 12.83% down from the prior year.
  • Equity Average for Q1 2026 was -$10.5 million at TriSalus Life Sciences, up from -$30.3 million in the prior quarter.
  • Over five years, Equity Average peaked at -$9.4 million in Q4 2023 and troughed at -$191.5 million in Q2 2023.
  • A 5-year average of -$76.3 million and a median of -$30.6 million in 2024 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: soared 94.33% in 2023 and later tumbled 146.78% in 2024.
  • Year by year, Equity Average stood at -$165.5 million in 2022, then soared by 94.33% to -$9.4 million in 2023, then plummeted by 146.78% to -$23.2 million in 2024, then plummeted by 30.78% to -$30.3 million in 2025, then skyrocketed by 65.25% to -$10.5 million in 2026.
  • Business Quant data shows Equity Average for TLSI at -$10.5 million in Q1 2026, -$30.3 million in Q4 2025, and -$23.1 million in Q3 2025.